IL-17A-blocking antibody has been shown to be effective for chronic inflammatory diseases associated with excessive bone formation including spondyloarthropathy and psoriatic arthritis, suggesting the positive effect of IL-17A in bone formation26, 27; however, the role of IL-17A on bone formation has been unclear. This evidence concerns the gene IL17A and psoriatic arthritis.